FDA requires new warnings on GLP-1 drugs over rare risk of vision loss
The U.S. regulator FDA has required manufacturers of all GLP-1 receptor agonists, including Ozempic, Wegovy, Mounjaro and Zepbound, to add a warning to their labels about the possible risk of the rare eye disease NAION, which can cause irreversible vision loss. The decision is based on an analysis of 126 clinical trials involving more than 134,000 patients.
Nilufar Karimova